Insider · CIK 0002018766
Vincent Vultaggio
Files at ZNTL (Zentalis Pharmaceuticals, Inc.). First filing Feb 4, 2026, latest Feb 10, 2026.
In brief
Vincent Vultaggio files SEC Form 4 as officer at ZNTL (Zentalis Pharmaceuticals, Inc.). Since Feb 4, 2026, Vincent Vultaggio has reported 0 open-market buys worth $0 and 2 open-market sells worth $105k, the latest filed on Feb 10, 2026.
A track record needs three past buys with six months of prices behind them; Vincent Vultaggio has 0, so none is measured yet.
The newest scored trade: sold $98k of ZNTL on Feb 6, 2026, filed Feb 10, 2026, scored 25 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $105k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ZNTL: Zentalis Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 25Weak | Zentalis Pharmaceuticals, Inc. | $98k 40,224 shares | -22% | +130% from low-36% from high | |
| 10Weak | Zentalis Pharmaceuticals, Inc. | $7,875 3,096 shares | -2% | +141% from low-33% from high |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | ZNTL Zentalis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -29,951 | $2.43 | $73k | 156,779 | Feb 10, 2026 |
| Feb 9, 2026 | ZNTL Zentalis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -3,379 | $2.39 | $8,086 | 153,400 | Feb 10, 2026 |
| Feb 10, 2026 | ZNTL Zentalis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -6,894 | $2.42 | $17k | 146,506 | Feb 10, 2026 |
| Feb 2, 2026 | ZNTL Zentalis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -2,540 | $2.55 | $6,477 | 187,286 | Feb 4, 2026 |
| Feb 3, 2026 | ZNTL Zentalis Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -556 | $2.52 | $1,398 | 186,730 | Feb 4, 2026 |
| Jan 8, 2026 | ZNTL Zentalis Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 9, 2026 |
Questions about Vincent Vultaggio
Answered from the filings on this page, as of the latest one.
Is Vincent Vultaggio buying or selling?
In the last 12 months Vincent Vultaggio reported 0 open-market buys worth $0 and 2 open-market sells worth $105k on SEC Form 4; the latest was sold $98k of ZNTL on Feb 6, 2026. Grants, option exercises and tax withholding are not counted.
How did Vincent Vultaggio's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Vincent Vultaggio has 0.
Where does Vincent Vultaggio file Form 4?
Vincent Vultaggio has filed Form 4 at ZNTL (Zentalis Pharmaceuticals, Inc.) as PAO and PFO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.